Home How RBC Capital Called A 50% Gain In This Biotech Stock
 

Keywords :   


How RBC Capital Called A 50% Gain In This Biotech Stock

2015-04-02 14:18:31| Biotech - Topix.net

Shares of Dyax Corp. closed up more than 53 percent on Wednesday after the company announced positive results from an early-stage test of its drug DX-2930 on treatment of Hereditary Angioedema . Benzinga had the chance to speak with Dyax's Executive Vice President of R&D, Dr. Burt Adelman, about what the results mean for the company.

Tags: this called stock capital

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Phibro Animal Health completes acquisition of Zoetis medicated feed additive portfolio
05.11November/December 2024 Digital Edition of National Hog Farmer now available
05.11Registration Now Open for RadTech 2025
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Public Advisory Number 7A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
More »